Autogenic Living Scaffolds and Living Tissue Matrices: Methods and Uses Thereof
a technology of living scaffolds and living tissue matrices, applied in the field of living scaffolds, can solve the problems of limited durability of mechanical devices, imperfect matches, tissue complications, etc., and achieve the effect of preventing host rejection and tightening and strengthening
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example
Using the ALS as a Scaffold for Creating a Nerve Graft
[0112]There is currently no proper treatment for spinal cord injury. Limited spinal cord regeneration has been achieved in a small number of patients through physical rehabilitation and training, peripheral nerve grafts, and by transplanting fetal spinal cord tissue. Most patients are limited to being dependent on the use of a wheelchair and even on devices that sustain / replace lost autonomic function.
[0113]There are a number of approaches in current research into treatments for spinal cord injury. The current limitation of all these approaches is that they restore only partial and generally minimal functionality to the injured spinal cord. The first clinical trials for the treatment of spinal cord injury began on Jul. 11, 2002, in Australia by transplanting olfactory ensheathing glia into patients' spinal cords. The limitation of this approach is that it takes several years to restore some of the functions lost due to the spinal...
example 1a
Serum-Free Chemically-Defined Medium for Growing Fibroblast ALS—“fALS Medium” or “Matrix Media”
[0122]One embodiment of a chemically defined media formulation in accordance with the present invention contains:
[0123]A 3:1 ratio of DMEM (high glucose (4.5 g / L); with L-glutamine and sodium pyruvate) and Ham's F12 medium supplemented with the following components:[0124]4.2×10−10M Epidermal Growth Factor (in human serum albumin)[0125]2.8×10−10M Basic Fibroblast Growth Factor[0126]8.6×10−5M insulin[0127]1.0×10−1M dexamethasone[0128]3.2×10−4M L-ascorbic acid phosphate magnesium salt n-hydrate[0129]2×10−10M L-3,3′,5-triiodothyronine[0130]104M ethanolamine[0131]3.9×10−8M selenious acid[0132]4×10−3M Glutamax™[0133]3.3×10−6M glutathione (reduced)[0134]1% penicillin / streptomycin / amphotericin B
[0135]In addition, other embodiments and variations of the above-listed medium may contain additional components, such as any one or more of the following components:[0136]Platelet derived growth factor (PD...
example 1b
Serum-Free Chemically-Defined Medium for Growing Neuronal Cells / Tissue—“Neural Medium”
[0141]One embodiment of a chemically defined media formulation in accordance with the present invention contains:
[0142]A 2:3 ratio of DMEM / F12 and Neurobasal Medium (see Gibco-Invitrogen Corporation at www.invitrogen.com, or www.invitrogen.co.jp / focus / 161006.pdf) supplemented with the following components:[0143]3×10−10M Fibroblast Growth Factor 2[0144]8.5×10−6M D(+)galactose[0145]6.0×10−8M progesterone[0146]6.0×10−7M retinyl acetate[0147]9.0×10−8M corticosterone[0148]1.0×10−4M putrescine[0149]1.0×10−5M carnitine[0150]1.3×10−5M linoleic Acid[0151]4.3×10−6M linolenic Acid[0152]4.0×10−6M biotin[0153]4.0×10−6M Trolox[0154]1% penicillin / streptomycin / amphotericin B
In addition, other embodiments and variations of the above-listed medium may contain additional components, and concentrations may vary as required.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More